sb-3ct-compound and Tuberculosis--Meningeal

sb-3ct-compound has been researched along with Tuberculosis--Meningeal* in 2 studies

Other Studies

2 other study(ies) available for sb-3ct-compound and Tuberculosis--Meningeal

ArticleYear
Adjunctive role of MMP-9 inhibition along with conventional anti-tubercular drugs against experimental tuberculous meningitis.
    International journal of experimental pathology, 2016, Volume: 97, Issue:3

    Tuberculous meningitis (TBM) is an outcome of neuroinflammatory degeneration caused due to Mycobacterium tuberculosis infection and leads to death or neurological disabilities in the affected individuals. It causes the highest morbidity and mortality amongst all forms of tuberculosis. Matrix metalloproteinase-9 levels increase and cause inflammatory destruction during progression of the disease. Although corticosteroids are usually given as an adjuvant therapy to overcome these complications, treatment outcome is contradictory. This study was designed to evaluate whether specific inhibition of MMP-9 can be beneficial in management of the disease. MMP-9 levels were inhibited using SB-3CT or dexamethasone along with conventional drugs for treatment of tuberculous meningitis. Both SB-3CT and dexamethasone decreased the elevated levels of MMP-9 in sera and tissues of the infected mice. However, dexamethasone administration had an inhibitory effect on bacillary clearance, while SB-3CT potentiated the bacillary clearance, suggesting that MMP-9, if specifically inhibited, can be beneficial in the management of TBM.

    Topics: Animals; Antitubercular Agents; Dexamethasone; Disease Models, Animal; Drug Synergism; Heterocyclic Compounds, 1-Ring; Matrix Metalloproteinase 9; Mice; Mycobacterium tuberculosis; Protease Inhibitors; Sulfones; Tuberculosis, Meningeal

2016
Title: role of matrix metalloproteinase -9 in progression of tuberculous meningitis: a pilot study in patients at different stages of the disease.
    BMC infectious diseases, 2016, 11-29, Volume: 16, Issue:1

    TBM (Tuberculous meningitis) is severe form of tuberculosis causing death of one third of the affected individuals or leaving two-third of the survivors disabled. MMP-9 (Matrix metalloproteinase-9) is produced by the central nervous system in a variety of inflammatory conditions and has a role in the breakdown of extracellular matrix and blood-brain barrier.. In this study, the levels of MMP-9 and its inhibitor, TIMP-1 (tissue inhibitor of metalloproteinases-1), were screened using zymography and reverse zymography in cerebrospinal fluid and serum of tuberculous meningitis patients at different stages of the disease. Further, role of MMP-9 as therapeutic target was studied in C6 glioma cells infected with Mycobacterium tuberculosis H. MMP-9 levels in patients were increased as the disease progressed to advanced stages. The infection led to increased MMP-9 levels in C6 glioma cells and specific inhibition of MMP-9 by SB-3CT augmented bacillary clearance when used along with antitubercular drugs.. MMP-9 plays a prominent role in progression of tuberculous meningitis from initial to advanced stages. Increased levels of MMP-9 during advancement of the disease leads to degeneration of nervous tissue and blood brain barrier disruption. Hence, MMP-9 can be considered as a therapeutic target for efficient management of TBM and can be explored to inhibit further progression of the disease if used at an early stage.

    Topics: Adult; Antitubercular Agents; Case-Control Studies; Cell Line, Tumor; Dexamethasone; Disease Progression; Female; Heterocyclic Compounds, 1-Ring; Humans; Male; Matrix Metalloproteinase 9; Matrix Metalloproteinase Inhibitors; Middle Aged; Molecular Targeted Therapy; Mycobacterium tuberculosis; Pilot Projects; Sulfones; Tissue Inhibitor of Metalloproteinase-1; Tuberculosis, Meningeal

2016